MAA868

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Atrial FibrillationThrombotic Disorders

Phase 2

Prevention of Thromboembolic Events in Total Knee Replacement Patients

WithdrawnNCT03393481

Novartis PharmaceuticalsThrombotic Disorders

Start: 2018-10-03End: 2020-04-17Updated: 2020-10-08

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

WithdrawnNCT03398434

Novartis PharmaceuticalsAtrial Fibrillation

Start: 2018-10-16End: 2020-01-30Updated: 2020-10-08